Acquisition

Cancer biotech Vesicor goes public via Black Hawk SPAC merger

What's the deal? Vesicor TherapeuticsDealroom has a profile for this one. Try Dealroom →, an early-stage cancer biotech, has closed its merger with Black Hawk Acquisition CorporationDealroom has a profile for this one. Try Dealroom →, a blank-check company, taking Vesicor public. Black Hawk shareholders approved the deal on October 13, 2026, and it closed on November 19. Terms were not disclosed.

Why now? The merger gives Vesicor access to public markets as it prepares to begin IND-enabling studies for its lead candidate. "Closing this transaction gives Vesicor access to the public markets at the point where the Company needs it most," said Chairman Warren Hosseinion, Sr.

What's the endgame? Founded in 2008 and based in San Gabriel, California, Vesicor develops p53-based cancer therapeutics delivered via precision-engineered microvesicles. Its lead candidate, ecm-RV/p53, is being advanced toward an Investigational New Drug application with the US Food and Drug Administration.

As part of the deal, Black Hawk moved its registration from the Cayman Islands to Delaware and took the Vesicor name. The company's stock is expected to begin trading on the Nasdaq Capital Market under the ticker "VESI" on November 23.

Vesicor will be led by chief executive officer Michael Tolentino, with founder Luo Feng as chief scientific officer and Mitch Creem as chief financial officer. "Our priority as a public company is clear: advance ecm-RV/p53 through IND-enabling studies and toward an IND submission to the FDA," Tolentino said.

The signal: The deal shows SPAC mergers remain a route for pre-clinical biotechs to reach public markets ahead of costly trials — a path that hands early-stage companies capital, but also the scrutiny of public shareholders before a drug has entered the clinic.

Read more: Business Insider

Image credit: Generated with Gemini

More top stories